NewAmsterdam Pharma (NAMS) Payables (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Payables of $58.3 million for Q1 2026, down 11.96% sequentially from $66.2 million in Q4 2025, and up 96.96% YoY from $29.6 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Payables (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Payables for 6 years, with the latest figure at $58.3 million in Q1 2026.
- Quarterly Payables rose 96.96% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 96.96% YoY) and the FY2025 annual result came in at $66.2 million, up 56.76% from the prior year.
- Payables declined to $58.3 million in Q1 2026 per NAMS's latest filing, from $66.2 million in the prior quarter.
- Over five years, Payables peaked at $66.2 million in Q4 2025 and troughed at $18.9 million in Q4 2022.
- A 5-year average of $37.3 million and a median of $30.4 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2025 and 2026: Payables declined 28.82% in 2025, then soared 96.96% in 2026.
- Over 5 years, Payables stood at $18.9 million in 2022, then soared by 56.22% to $29.5 million in 2023, then soared by 43.26% to $42.3 million in 2024, then soared by 56.76% to $66.2 million in 2025, then fell by 11.96% to $58.3 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $58.3 million, $66.2 million, and $48.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 59.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.87 Mn |
| Mar 31, 2026 | 58.32 Mn |
| Dec 31, 2025 | 66.24 Mn |
| Sep 30, 2025 | 47.99 Mn |
| Jun 30, 2025 | 26.83 Mn |
| Mar 31, 2025 | 29.61 Mn |
| Dec 31, 2024 | 42.26 Mn |
| Sep 30, 2024 | 25.94 Mn |
| Jun 30, 2024 | 28.82 Mn |
| Mar 31, 2024 | 41.60 Mn |
| Dec 31, 2023 | 29.50 Mn |
| Jun 30, 2023 | 31.12 Mn |
| Dec 31, 2022 | 18.88 Mn |
| Dec 31, 2021 | 11.24 Mn |